At AGC Biologics, we are continuing to expand our manufacturing capabilities and capacities to serve clients across the globe. We caught up with Ben Clauberg, VP Business Development Europe, at CPHI, where he provided updates on the industry-leading 10k L microbial manufacturing capacities now available at our Heidelberg site, and the expansion of our mammalian single-use, mRNA, and cell and gene therapy manufacturing facility in Yokohama, Japan. Watch the interview to see how you can reserve ca

Is biopharma facing a microbial manufacturing crunch?